LY2623091 + tadalafil

LY2623091 + tadalafil is a **combination drug composed of LY2623091 and tadalafil**. Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor primarily used for the treatment of erectile dysfunction, benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH)[1][5]. Tadalafil works by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), promoting relaxation of smooth muscle and vasodilation, particularly in the corpus cavernosum and pulmonary vasculature. LY2623091 is an investigational compound from Eli Lilly; however, publicly available information on its precise mechanism of action, clinical stage, or detailed pharmacology is not established in scientific literature or major drug databases as of the current date.